Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis
Open Access
- 24 July 2021
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74 (4), 734-742
- https://doi.org/10.1093/cid/ciab646
Abstract
Recently emerged SARS-CoV-2 variants may pose a threat to immunity. A systematic landscape of neutralizing antibodies against emerging variants is needed. We systematically searched for studies that evaluated neutralizing antibodies titers induced by previous infection or vaccination against SARS-CoV-2 variants and collected individual data. We identified 106 studies meeting the eligibility criteria. Lineage B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta) significantly escaped natural-infection-mediated neutralization, with an average of 4.1-fold (95% CI: 3.6-4.7), 1.8-fold (1.4-2.4), and 3.2-fold (2.4-4.1) reduction in live virus neutralization assay, while neutralizing titers against B.1.1.7 decreased slightly (1.4-fold, 95%CI: 1.2-1.6). Serum from vaccinees also led to significant reductions in neutralization of B.1.351 across different platforms, with an average of 7.1-fold (5.5-9.0) for non-replicating vector platform, 4.1-fold (3.7-4.4) for mRNA platform, and 2.5-fold (1.7-2.9) for protein subunit platform. Neutralizing antibodies levels induced by mRNA vaccines against SARS-CoV-2 variants were similar, or higher, than that derived from naturally-infected individuals.Keywords
Funding Information
- National Science Fund for Distinguished Young Scholars (81525023)
- Program of Shanghai Academic Research Leader (18XD1400300)
- National Science and Technology Major Project (2018ZX10713001-007, 2017ZX10103009-005, 2018ZX10201001-010)
- National Institutes of Health (R01 AI135115)
This publication has 32 references indexed in Scilit:
- Comparison of Four SARS-CoV-2 Neutralization AssaysVaccines, 2020
- Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trialsPublished by Cold Spring Harbor Laboratory ,2020
- Escape from neutralizing antibodies by SARS-CoV-2 spike protein variantseLife, 2020
- The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 InfectionJACC: Basic To Translational Science, 2020
- Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal modelScience, 2020
- A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiologyNature Microbiology, 2020
- Author Correction: A new coronavirus associated with human respiratory disease in ChinaNature, 2020
- A new coronavirus associated with human respiratory disease in ChinaNature, 2020
- Data, disease and diplomacy: GISAID's innovative contribution to global healthGlobal Challenges, 2017
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009